UCBJF:OTCMKTS
UCB SA
USD 235,94
arrow_downward
-1,03%(-2,46) 1D
13 Okt., 10:35:17 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UCBJF...
Open
USD 235,94
High
USD 235,94
Low
USD 235,94
Mkt. cap
39,20 mjd
Avg. vol.
140,00
Volume
61,00
52-wk high
USD 345,39
52-wk low
USD 219,60
Beta
0,58
Shares outstanding
194,51 m
No. of employees
9 k
Open
USD 235,94
High
USD 235,94
Low
USD 235,94
Mkt. cap
39,20 mjd
Avg. vol.
140,00
Volume
61,00
52-wk high
USD 345,39
52-wk low
USD 219,60
Beta
0,58
Shares outstanding
194,51 m
No. of employees
9 k
News stories
From web sources and news partners
ad-hoc-news.de
·
7 uur gelede
ING sets EUR 304.00 target for UCB stock with 48.87 percent upside
ad-hoc-news.de
·
12 uur gelede
UCB stock pre-market at EUR 203.40
ad-hoc-news.de
·
1 dag gelede
UCB dedicated Georgia site. UCB stock sits below EUR 206.70
AD HOC NEWS
·
3 dae gelede
UCB stock holds EUR 203.95 in weekend trading
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB SA
CEOJean-Christophe Tellier
Employees9 k
Founded18 Jan. 1928
Headquarters-
SectorPharmaceutical industry
Websiteucb.com